Researchers identify therapy that shrinks tumors in patients with multiple myeloma

March 8, 2017
Credit: Mayo Clinic

Mayo Clinic researchers have found that an experimental drug, LCL161, stimulates the immune system, leading to tumor shrinkage in patients affected by multiple myeloma. The findings are published in Nature Medicine.

Multiple myeloma is a blood cancer that affects - that normally produce antibodies to fight infection. Rather than produce helpful antibodies, the cancer cells, as they grow, secrete large amounts of a single antibody that accumulate in the body, causing kidney problems and infections.

"The drug, LCL161, was initially developed to promote tumor death," says Marta Chesi, Ph.D., a Mayo Clinic biochemist and lead author of the study of 25 Multiple Myeloma patients. "However, we found that the drug does not kill directly. Rather, it makes them more visible to the immune system that recognizes them as foreigner invaders and eliminates them."

Mayo Clinic researchers will conduct a follow-up clinical trial of LCL161 in combination with an inhibitor of immune checkpoints that has been widely used in many cancer treatments to evaluate if LCL161 could represent a potential new treatment option.

"The model for preclinical studies to predict with great accuracy which drugs would work in the clinic was developed a decade ago," says Dr. Chesi. "And it has been instrumental in the prioritization of which experimental therapeutics should be tested in patients with multiple myeloma."

The research highlights the importance of studying the effects of drugs not only on the tumor cells in a culture plate, but also on the interaction of the tumor cells with their own microenvironment. The finding that LCL161 is active against suggests that similar drugs may have broader clinical activity than previously thought.

Explore further: New treatments to extend life for multiple myeloma patients

More information: Marta Chesi et al. IAP antagonists induce anti-tumor immunity in multiple myeloma, Nature Medicine (2016). DOI: 10.1038/nm.4229

Related Stories

New treatments to extend life for multiple myeloma patients

February 10, 2017
Multiple myeloma is a cancer of the plasma cells that reside inside bone marrow. Plasma cells produce certain proteins that build up the immune system. In abnormal quantities, these proteins damage the body and compromise ...

Study shows that choice of medical center impacts life expectancy of multiple myeloma patients

October 26, 2016
People diagnosed with multiple myeloma are more likely to live longer if they are treated at a medical center that sees many patients with this blood cancer. Mayo Clinic researchers published these findings today in the Journal ...

Preclinical tests may lead to new approach to treat CNS lymphoma

August 12, 2013
A drug recently approved for use in multiple myeloma is now being tested for its ability to fight central nervous system (CNS) lymphoma, a deadly cancer of the immune system that can affect the brain, spinal cord and fluid, ...

Empliciti approved for multiple myeloma

November 30, 2015
(HealthDay)—Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat the blood cancer multiple myeloma. The drug is only approved for patients who ...

Researchers discover underlying cause of myeloma

February 11, 2016
Yale Cancer Center researchers have identified what causes a third of all myelomas, a type of cancer affecting plasma cells. The findings, published Feb. 10 in the New England Journal of Medicine, could fundamentally change ...

New model for understanding myeloma

October 12, 2016
All cancers originate from an earlier, or precursor, state—such as a benign or asymptomatic condition. To develop new approaches to cancer prevention, scientists have attempted to grow tumor cells from  precursor states ...

Recommended for you

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

Many pelvic tumors in women may have common origin—fallopian tubes

October 17, 2017
Most—and possibly all—ovarian cancers start, not in ovaries, but instead in the fallopian tubes attached to them.

Researchers find novel mechanism of resistance to anti-cancer drugs

October 17, 2017
The targeted anti-cancer therapies cetuximab and panitumumab are mainstays of treatment for advanced colorectal cancer, the second leading cause of cancer-related deaths in the United States. However, many patients have tumors ...

New bowel cancer drug target discovered

October 17, 2017
Researchers at the Francis Crick Institute have discovered a new drug target for bowel cancer that is specific to tumour cells and therefore less toxic than conventional therapies.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.